Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by lonc17on Mar 03, 2006 12:44am

716 Views

Post# 10454068

From a Marsden website

This sounds good… A Phase I trial of systemically administered Reovirus Type 3 (Dearing) is nearing completion and will lead to further trials of intravenous Reovirus plus cytotoxic chemotherapy. https://www.icr.ac.uk/research/research_sections/clincal_research/teams/head_and_neck_unit/index.shtml

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario